nct_id: NCT06526793
age: Adults
cancer_center_accrual_goal_upper: 0
curated_on: '2024-07-30'
study_start_date: '2024-11-27'
study_completion_date: null
data_table4: Interventional
drug_list:
  drug:
  - drug_name: 'Drug: Surovatamig'
long_title: A Modular Phase 2, Single-arm, Multicenter, Open-label Study to Evaluate
  the Efficacy and Safety of Surovatamig (AZD0486) in Participants With Relapsed or
  Refractory (R/R) B-cell Non-Hodgkin Lymphoma (SOUNDTRACK-B)
last_updated: '2025-10-20'
management_group_list:
  management_group:
  - is_primary: Y
    management_group_name: Group1
oncology_group_list:
  oncology_group:
  - group_name: Group1
    is_primary: N
phase: PHASE2
principal_investigator: NA
principal_investigator_institution: AstraZeneca
program_area_list:
  program_area:
  - is_primary: Y
    program_area_name: Program1
protocol_id: 0
protocol_ids: []
protocol_no: ''
protocol_target_accrual: 240
protocol_type: INTERVENTIONAL
prior_treatment_requirements:
- '1. Key Inclusion Criteria:'
- '* Aged 18 years old and above'
- '* Histologically confirmed relapsed refractory FL (Module 1) and LBCL (Module 2)
  after at least 2 prior lines of therapy'
- '* ECOG performance status 0 to 2'
- '* Locally confirmed CD-19 expression in lymphoma cells after progression from last
  CD 19 directed therapy'
- '* FDG-avid disease with at least one bi-dimensionally measurable nodal lesion (defined
  as \> 1.5 cm in its longest dimension), or extranodal lesion (defined as \> 1.0
  cm in its longest dimension)'
- "* Adequate hematological function: ANC \u2265 1000/mm3, platelets"
- "* 75,000/mm3, hemoglobin \u2265 9 g/dL. Transfusion and/or growth factor are allowed\
  \ but counts must be stable for at least 72 hours afterwards prior to screening"
- "* Adequate liver function: total bilirubin \\<1.5x ULN, AST/ALT \u2264 3xULN or\
  \ \\< 5 \xD7 ULN in the presence of lymphoma involvement of the liver"
- "* Adequate renal function: creatinine clearance (CrCl) of \u2265 45 mL/min"
- "* Adequate cardiac function, defined as left ventricular ejection fraction (LVEF)\
  \ \u2265 45% by echocardiogram or MUGA"
- The above is a summary, other inclusion criteria details may apply.
- 'Exclude - 2. Key Exclusion Criteria:'
- Exclude - * Diagnosis of CLL, Burkitt lymphoma, or Richter's transformation
- Exclude - * Active CNS involvement by B-NHL
- Exclude - * Leukemic presentation of B-NHL
- Exclude - * History or presence of clinically relevant CNS pathology such as epilepsy,
  seizure, paresis, aphasia, stroke, severe brain injuries, dementia, neurodegenerative
  disorder including Parkinson's disease, cerebellar disease, organic brain syndrome,
  or psychosis or other severe mental illness
- Exclude - * Prior therapy with T-cell engager (TCE) within 8 weeks, autologous Hematopoietic
  Stem Cell Transplantation (HSCT) within 12 weeks, CAR T- cell therapy within 6 months,
  or prior allogeneic HSCT within 24 weeks of first dose of surovatamig
- Exclude - * Requires chronic immunosuppressive therapy
- "Exclude - * Unresolved non hematological AEs \u2265 Grade 2 from prior therapies;\
  \ history of \u2265 Grade 3 CRS or neurotoxicity from prior CAR-T or TCE therapy"
- Exclude - * History of major cardiac abnormalities.
- Exclude - * If female, participant must not be pregnant or breastfeeding.
- Exclude - The above is a summary, other exclusion criteria details may apply.
short_title: Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory
  (R/R) B-cell NHL
site_list:
  site: []
sponsor_list:
  sponsor:
  - is_principal_sponsor: Y
    sponsor_name: AstraZeneca
    sponsor_protocol_no: ''
    sponsor_roles: sponsor
staff_list:
  protocol_staff: []
status: open to accrual
summary: 'This is a Phase 2 global, multi-center, open-label study to assess the efficacy,
  safety and tolerability of Surovatamig (AZD0486) monotherapy in adult participants
  with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL) who have received at
  least two prior lines of therapies. The study has 2 Modules: Module 1 for FL and
  Module 2 for LBCL.'
treatment_list:
  step:
  - step_internal_id: 111
    step_code: '1'
    step_type: Registration
    arm:
    - arm_code: 'Module 1: Surovatamig Monotherapy in Participants with Relapsed or
        Refractory Follicular Lymphoma'
      arm_internal_id: 0
      arm_description: In Module 1, the efficacy and safety of surovatamig at the
        RP2D will be evaluated in R/R FL. Surovatamig will be administered as intravenous
        infusion.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Surovatamig'
        level_internal_id: 0
        level_suspended: N
    - arm_code: 'Module 2: Surovatamig Monotherapy in Participants with Relapsed or
        Refractory LBCL'
      arm_internal_id: 1
      arm_description: In Module 2, the efficacy and safety of surovatamig at the
        RP2D will be evaluated in R/R LBCL. Surovatamig will be administered as intravenous
        infusion.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Surovatamig'
        level_internal_id: 0
        level_suspended: N
    match:
    - clinical:
        age_numerical: '>=18'
        disease_status:
        - Recurrent
        - Refractory
        oncotree_primary_diagnosis: Lymphoid Neoplasm
